Business
PetLife Publishes Two White Papers on History and Production of Escozine for Pets(TM)
PetLife Publishes Two White Papers on History and Production of Escozine for Pets(TM).
About this update from Petlife Pharmaceuticals Inc
[{"type":"text","content":"\n \n \n PetLife Publishes Two White Papers on History and Production of Escozine for Pets(TM)\n \n \nPetLife Publishes Two White Papers on History and Production of Escozine for Pets(TM)\n \n BEVERLY HILLS, CA--(Marketwired - Sep 17, 2014) - PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) today announced it has published two white papers that explain the science underlying Escozine for Pets™. The first of which is History of Escozine For Pets, and the second is Stages of Production of Escozine For Pets which contains a highly detailed and scientifically technical analysis of the production and polarization process from start to finish. \n Both are available on the Company's website at: http://www.petlifepharma.com/escozine%E2%84%A2-science.html. \n PetLife plans to publish its next white paper on the zoological, biological and biotech science of scorpions, featuring its unique Blue Scorpion Reservation on twelve acres in the Dominican Republic containing over 40,000 Blue Scorpions.\n Highlights of History of Escozine for Pets White Paper:\n \n \n PetLife Pharmaceuticals and its sister company, Medolife, are the only companies in the world with the patented Escozine formulation based upon Blue Scorpion Venom. Escozine For Pets™ is solely owned and commercialized by PetLife Pharmaceuticals.\n \nPetLife Founder and CEO Arthur Mikaelian, Ph.D. is the scientist who completed the R&D and attained the legal registration to commercialize the Blue Scorpion venom-based product under the name of Escozine For Pets. \n \nEscozine™ and Escozine for Pets utilize the licensed, patented polarization technology which produces a far more effective product than Labiofams's Blue Scorpion venom in Escozul and Vidatox.\n \nPetLife, in affiliation with Medolife, has its own independent source of Blue Scorpion venom in the Dominican Republic, the world's first Scorpion reservation of 50,000 square meters that can produce millions of doses to meet global demand.\n \nThe world renowned Atheris Laboratory in Switzerland has provided scientific confirmation to Medolife that Blue Scorpion venom blocks sodium and potassium volt gate channels. This action causes actual shrinkage of tumors and inhibits cancer cell proliferation.\n \nThe report indicates that Dominican Blue Scorpion venom has a three times higher concentration of Chl...